natgillin/translations-raw huggingface dataset:
The process according to claim 14, wherein the compound of Formula III is present at an amount of 5 moles per mole of compound of Formula IIa. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što je navedeni spoj Formule III prisutan u količini od 5 mol po molu spoja Formule II.
The process according to claim 17, wherein said lipase from Candida is present at an amount ranging from about 1,000 to 1,000,000 U/mmol for Candida cylindracea (CCL), and ranges from about 100 to 100,000 U/mmol for Candida antartica of type B (CALB). 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što je navedena lipaza iz Candida prisutna u rasponu količina od otprilike 1.000 do 1.000.000 U/mmol za kvasac Candida cilindracea (CCL), te u rasponu od otprilike 100 do 100.000 U/mmol za kvasac Candida antartica tipa B (CALB).
and preferably also wherein 
i poželjno također pri čemu
R2a and R2b are taken together with the carbons to which they are attached to form a 4-10 membered partially or fully saturated mono or bicyclic ring, optionally containing one or more heteroatoms and optionally substituted with one or more Ra and/or Rb, which ring is preferably a cyclopentane, pyrrolidine, imidazolidine, 1,3-dioxolane, oxazolidine, tetrahydrofuran, cyclohexane, morpholine, piperidine, dioxane, oxathiazinane, piperazine, cycloheptane, cycloheptene, azepane, tetrahydroazepine, diazepane, cyclooctane, cyclooctene, azocane, hexahydroazocine, diazocane or hexahydrodiazocine ring; optionally substituted with one or more Ra and/or Rb. 
R2a i R2b su uzeti zajedno s atomima ugljika na koje su vezani tako da tvore 4-10 člani djelomično ili potpuno zasićen mono ili biciklički prsten, koji proizvoljno sadrži jedan ili više heteroatoma i proizvoljno supstituiran s jednim ili više Ra i/ili Rb, te je navedeni prsten poželjno ciklopentan, pirolidin, imidazolidin, 1,3-dioksolan, oksazolidin, tetrahidrofuran, cikloheksan, morfolin, piperidin, dioksan, oksatiazinan, piperazin, cikloheptan, ciklohepten, azepan, tetrahidroazepin, diazepan, ciklooktan, ciklookten, azokan, heksahidroazocin, diazokan ili heksahidrodiazocin prsten; proizvoljno supstituiran s jednim ili više Ra i/ili Rb.
preferably wherein R1 is H or R50; R50 is -CH2OP(O)(OR11)2; and each R11 is independently for each occurrence Ra or a monovalent cationic group; or two R11, together with the atoms to which they are attached, form a 4-8 membered cyclic phosphate group, or two R11 together represent a divalent cationic group, more preferably each R11 is independently for each occurrence H, t -butyl, HOCH2CH2N(CH3)3+, Na+, Li+ or K+. 
poželjno pri čemu R1 je H ili R50; R50 je -CH2OP(O)(OR11)2; i svaki R11 je neovisno za svaku pojavu Ra ili jednovalentna kationska skupina; ili dva R11, zajedno s atomima na koje su oni vezani, tvore 4-8 članu cikličku fosfatnu skupinu, ili dva R11 zajedno predstavljaju dvovalentnu kationsku skupinu, poželjnije svaki R11 je neovisno za svaku pojavu H, t-butil, HOCH2CH2N(CH3)3+, Na+, Li+ ili K+.
The compound according to any one of claims 1-17 or the pharmaceutical composition of claim 18 for use in treating a JAK kinase-mediated disease, allograft transplant rejection in a transplant recipient, T-cell mediated autoimmune disease or a disease and/or disorder of the eye. 
Spoj prema bilo kojem od zahtjeva 1-17 ili farmaceutski pripravak prema zahtjevu 18 naznačen time da je za uporabu za liječenje bolesti posredovane s JAK kinazom, odbacivanja transplantata alografta kod primatelja transplantata, autoimune bolesti posredovane T-stanicama ili bolesti i/ili poremećaja oka.
wherein the pharmaceutical dosage form is administered twice daily, once daily or less frequently. 
pri čemu se farmaceutski oblik doziranja daje dva puta dnevno, jednom dnevno ili rjeđe.
The pharmaceutical dosage form for use according to claim 1 or 2, which comprises a liquid core encapsulated by a solid material, wherein the pharmacologically active agent according to general formula (I) is dispersed in the liquid core. 
Farmaceutski oblik doziranja za upotrebu prema zahtjevu 1 ili 2, koji sadrži tekuću jezgru enkapsuliranu s krutim materijalom, naznačen time da je farmakološki aktivna tvar u skladu s općom formulom (I) dispergirana u tekućoj jezgri.
The pharmaceutical dosage form for use according to any of the preceding claims, which comprises a surfactant in an amount of at least 0.001 wt.-%, based on the total weight of the pharmaceutical dosage form. 
Farmaceutski oblik doziranja za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da sadrži surfaktant u količini od najmanje 0.001 tež. %, na temelju ukupne težine farmaceutskog oblika doziranja.
The pharmaceutical dosage form for use according to any of the preceding claims, wherein the pharmacologically active agent according to general formula (I) has a stereochemistry according to general formula (I') wherein R is defined as in claim 1. 
Farmaceutski oblik doziranja za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da farmakološki aktivna tvar u skladu s općom formulom (I) ima stereokemijsku konfiguraciju u skladu s općom formulom (I') [image] pri čemu je R definiran kao u zahtjevu 1.
The pharmaceutical dosage form for use according to any of the preceding claims, which releases under in vitro conditions in 900 mL artificial gastric juice at pH 1.2 after 30 minutes at least 80 wt.-% of the pharmacologically active agent according to general formula (I), based on the total amount of the pharmacologically active agent according to general formula (I) originally contained in the dosage form. 
Farmaceutski oblik doziranja za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da oslobađa pod in vitro uvjetima u 900 mL umjetnog želučanog soka uz pH 1.2 nakon 30 minuta najmanje 80 tež.% farmakološki aktivne tvari prema općoj formuli (I), na temelju ukupne količine farmakološki aktivne tvari prema općoj formuli (I) koja je izvorno sadržana u obliku doziranja.
A pharmaceutical composition comprising the isolated antibody or fragment of any one of claims 1-7 and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži izolirano antitijelo ili fragment iz bilo kojeg od patentnih zahtjeva 1-7 i farmaceutski prihvatljiv nosač.
iv) systemic inflammatory condition, wherein optionally the systemic inflammatory condition is cytokine storm or hypercytokinemia, systemic inflammatory response syndrome (SIRS), graft versus host disease (GVHD), acute respiratory distress syndrome (ARDS), severe acute respiratory distress syndrome (SARS), catastrophic anti-phospholipid syndrome, severe viral infections, influenza, pneumonia, shock, or sepsis; 
iv) sistemsko upalno stanje, pri čemu je sistemsko upalno stanje opcionalno: citokinska oluja ili hipercitokinemija, sindrom sistemskog upalnog odgovora (SIRS), graft versus host sindrom (GVHD), akutni respiratorni distres sindrom (ARDS), teški akutni respiratorni distres sindrom (SARS), katastrofalni anti-fosfolipidni sindrom, teške virusne zaraze, gripa, upala pluća, stanje šoka ili sepsa;
Composition as in any claim hereinbefore, characterized in that, given the percentage in weight of CoQ10 and co-grinding adjuvant agent selected in the sucrose-esters class, the percentage in weight of the hydrophylic carrier in the maltodextrins class is provided to complete the 100% in weight. 
Pripravak prema bilo kojem prethodnom zahtjevu, naznačen time da je, s obzirom na težinski postotak CoQ10 i pomoćnog sredstva koje se zajednički usitnjava odabranog iz razreda sukroza-estera, predviđen težinski postotak hidrofilnog nosača iz razreda maltodekstrina tako da se dobije 100% težinski.
phosphorus and magnesium and 
fosfor i magnezij i
with or without Boswellia serrata. 
sa ili bez Boswellia serrata.
A peptide consisting of the amino acid sequence according to SEQ ID No. 1. 
Peptid koji se sastoji od odsječka aminokiseline u skladu sa SEQ ID br. 1.
The peptide according to claim 1, wherein said peptide is part of a fusion protein comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Peptid u skladu s patentnim zahtjevom 1, pri čemu je navedeni peptid dio fuzijske bjelančevine koja se sastoji od N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).
The peptide according to claim 1 or 2, the nucleic acid according to claim 3 or the expression vector according to claim 4 for use in medicine. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, nukleinska kiselina u skladu s patentnim zahtjevom 3 ili vektor ekspresije u skladu s patentnim zahtjevom 4 za upotrebu u medicini.
An isolated host cell which is not a human embryonic stem cell, comprising the nucleic acid according to claim 3 or the expression vector according to claim 4, wherein said host cell preferably is an antigen presenting cell, in particular a dendritic cell. 
Izolirana stanica domaćin, sastoji se od nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 3 ili ekspresijskog vektora u skladu s patentnim zahtjevom 4, pri čemu je navedena stanica po mogućnosti stanica koja eksprimira antigen, naročito dendritična stanica.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is the peptide according to claim 1. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen ili umjetnog spoja koji oponaša stanicu koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s patentnim zahtjevom 1.
The peptide according to claim 1 or 2, the nucleic acid according to claim 3, the expression vector according to claim 4, or the cell according to claim 6 for use in the treatment of cancer. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, nukleinska kiselina u skladu s patentnim zahtjevom 3 ili stanica u skladu s patentnim zahtjevom 6 za upotrebu u liječenju karcinoma.
The peptide according to claim 1 or 2, the nucleic acid according to claim 3, the expression vector according to claim 4, or the cell according to claim 6 for use in the manufacture of a medicament against cancer. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, nukleinska kiselina u skladu s patentnim zahtjevom 3, ekspresijski vektor u skladu s patentnim zahtjevom 4 ili stanica u skladu s patentnim zahtjevom 6 za upotrebu u proizvodnji lijekova protiv karcinoma.
The peptide according to claim 1 or 2, the nucleic acid according to claim 3, the expression vector according to claim 4, or the cell according to claim 6 for use according to claim 10, wherein said medicament is a vaccine. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, nukleinska kiselina u skladu s patentnim zahtjevom 3, ekspresijski vektor u skladu s patentnim zahtjevom 4 ili stanica u skladu s patentnim zahtjevom 6 za upotrebu u skladu s patentnim zahtjevom 10 pri čemu je navedeni lijek cjepivo.
The peptide according to claim 1 or 2, the nucleic acid according to claim 3, the expression vector according to claim 4, or the cell according to claim 6 for use according to claim 10 or 11, wherein said cancer is selected from astrocytoma, pilocytic astrocytoma, dysembryoplastic neuroepithelial tumor, oligodendrogliomas, ependymoma, glioblastoma multiforme, mixed gliomas, oligoastrocytomas, medulloblastoma, retinoblastoma, neuro-blastoma, germinoma, teratoma, gangliogliomas, gangliocytoma, central gangliocytoma, primitive neuroectodermal tumors (PNET), medulloblastoma, medulloepithelioma, neuro-blastoma, retinoblastoma, ependymoblastoma, tumors of the pineal parenchyma (e.g. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, nukleinska kiselina u skladu sa patentnim zahtjevom 3, ekspresijski vektor u skladu s patentnim zahtjevom 4, ili stanica u skladu s patentnim zahtjevom 6 za upotrebu u skladu s patentnim zahtjevom 10 ili 11, pri čemu je navedeni karcinom neki od sljedećih: astrocitom, pilocitični astrocitom, disembrioplastičan neuroepitelijalni tumor, oligodendrogliomi, ependimomi, glioblastom multiforme, miješani gliomi, oligoastrocitomi, meduloblastomi, retinoblastomi, neuroblastom, germinom, teratom, gangliogliomi, gangliocitom, centralni gangliocitom, primitivni neuroektodermalni tumori (PNET), meduloblastom, meduloepiteliom, neuroblastom, retinoblastom, ependimoblastom, tumori pinealnog parenhima, (npr.
pineocytoma, pineoblastoma), ependymal cell tumors, choroid plexus tumors, neuroepithelial tumors of uncertain origin, gliomatosis cerebri, astroblastoma or glioblastoma. 
pineocitom, pineoblastom), tumorni ependimalnih stanica, tumori koroidnog pleksusa, neuroepitelijalni tumori nepoznatog podrijetla, gliomatosis cerebri, astroblastom i glioblastom.
and at least one agrochemical selected from the group consisting of Trinexepac ethyl, Mandipropamid, Abamectin and Emamectin, with the proviso that the agrochemical is not abamectin or emamectin when the solvent is N-(B-hydroxyethyl)-lactamide. 
i najmanje jedno agrokemijsko sredstvo koje je odabrano iz skupine koja sadrži Trineksapak etil, Mandipropamid, Abamektin i Emamektin, uz uvjet da agrokemijsko sredstvo nije abamektin ili emamektin kada je otapalo N-(B-hidroksietil)-laktamid.
is not 2-hydroxypropyl when R2 is 2-hydroxypropyl; and R1 and R2 together with the nitrogen atom to which they are attached do not form a morpholinyl, pyrrolidinyl or piperidinyl unsubstituted ring. 
nije 2-hidroksipropil kada R2 je 2-hidroksipropil; i i R2 zajedno s atomom dušika na koji su vezani ne tvore nesupstituirani prsten morfolinil, pirolidinil ili piperidinil.
A composition according to any preceding claim, which further comprises a solvent selected from the group consisting of aliphatic solvents; straight or branched chain paraffins; cyclic hydrocarbons; aromatic solvents; phosphorus containing solvents; sulphur containing solvents; nitrogen containing solvents; aliphatic mono, di or triesters; aromatic mono and di esters; cyclic esters; cyclic, aliphatic and aromatic ketones; alkyl cyclohexanones, dialkyl ketones, acetoacetates, benzyl ketones,; acetophenone; alcohols; cycloalcohols; glycols; glycol ethers and their polymers; propylene glycols; glycol ether acetates; aromatic alcohols; carbonates; ethers and halogenated solvents. 
Pripravak prema bilo kojem prethodnom zahtjevu, naznačen time da nadalje sadrži otapalo odabrano iz skupine koju čine alifatska otapala; parafini ravnog ili razgranatog lanca; ciklički ugljikovodici; aromatska otapala; otapala koja sadrže fosfor; otapala koja sadrže sumpor; otapala koja sadrže dušik; alifatski mono-, di- ili triesteri; aromatski mono i di esteri; ciklički esteri; ciklički, alifatski i aromatski ketoni; alkil cikloheksanoni, dialkil ketoni, acetoacetati, benzil ketoni; acetofenon; alkoholi; cikloalkoholi; glikoli; glikol eteri i njihovi polimeri; propilen glikoli; glikol eter acetati; aromatski alkoholi; karbonati; eteri i halogenirana otapala.
A composition according to any preceding claim, which further comprises at least one compound selected from the group consisting of adjuvants, surfactants, polymers, thickening agents, dyestuffs or pigments, ultraviolet light absorbers, anti bacterial agents, salts, density modifiers, stenching or odour improving agents, taste modifiers, cosolvents, and humectants. 
Pripravak prema bilo kojem prethodnom zahtjevu, naznačen time da nadalje sadrži najmanje jedan spoj izabran iz skupine koja se sastoji od adjuvanata, surfaktanata, polimera, sredstava za zgušnjavanje, bojila ili pigmenata, sredstava za apsorbiranje ultraljubičastog svjetla, antibakterijskih sredstava, soli, sredstava za modifikaciju gustoće, sredstava za poboljšanje mirisa ili neugodnih mirisa, modifikatora okusa, ko-otapala, te humektanata.
A liposome for in vivo delivery of RNA to a vertebrate cell, the liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer comprises a lipid having a pKa in the range of 5.0 to 6.8 when measured as described in the section "pKa measurement" of the description; and (ii) the aqueous core includes a RNA which encodes an immunogen. 
Liposom za in vivo unos RNA u stanicu kralježnjaka, naznačen time što liposom koji ima lipidni dvosloj obuhvaća vodenu jezgru, gdje: (i) lipidni dvosloj sadrži lipid koji ima pKa u rasponu od 5,0 do 6,8 prilikom mjerenja, kao što je opisano u odjeljku "Mjerenje pKa " u Opisu izuma; i (ii) vodena jezgra sadrži RNA koja kodira imunogen.
The liposome of any preceding claim, wherein the immunogen elicits an immune response in vivo against a bacterium, a virus, a fungus or a parasite. 
Liposom u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što imunogen postiže imunosni odgovor in vivo protiv bakterije, virusa, gljivice ili parazita.
A compound as defined in claim 1 for use as a medicament. 
Tvar kako je definirana u patentnom zahtjevu 1 za uporabu kao lijek.
A compound of claim 1 or a pharmaceutically acceptable acid addition salt thereof for use in the treatment of neurodegenerative disorders in a mammal. 
Tvar iz patentnog zahtjeva 1 ili njena farmaceutski prihvatljiva sol dobivena adicijom kiseline za uporabu u liječenju neurodegenerativnih poremećaja u sisavaca.
A compound according to claim 4 for use in the treatment of Parkinson's disease or Huntington's disease in a mammal. 
Tvar u skladu s patentnim zahtjevom 4 za uporabu u liječenju Parkinsonove bolesti ili Huntingtonove bolesti u sisavaca.
A compound of claim 1 or a pharmaceutically acceptable acid addition salt thereof for use in the treatment of psychoses, impotence, renal failure, heart failure, hypertension, cognitive impairment, restless legs syndrome (RLS), periodic limb movement disorder (PLMD), movement disorders, poverty of movement, dyskinetic disorders, gait disorders, or intention tremor in a mammal. 
Tvar iz patentnog zahtjeva 1 ili njena farmaceutski prihvatljiva sol dobivena adicijom kiseline za uporabu u liječenju psihoze, impotencije, zatajenja bubrega, zatajenja srca, hipertenzije, kognitivnog oštećenja, sindroma nemirnih nogu (RLS), periodičnog poremećaja pokreta udova (PLMD), poremećaja pokreta, oskudnosti pokreta, diskinetičkih poremećaja, poremećaja hoda, ili intencijskog tremora u sisavaca.
A compound of claim 1, or a pharmaceutically acceptable acid addition salt thereof, for use in the treatment of depression, bipolar disorder and anxiety in a mammal. 
Tvar iz patentnog zahtjeva 1, ili njena farmaceutski prihvatljiva sol dobivena adicijom kiseline, za uporabu u liječenju depresije, bipolarnog poremećaja i tjeskobe u sisavaca.
A compound of claim 1, or a pharmaceutically acceptable acid addition salt thereof, for use in the treatment of cognitive impairment associated with a disorder or disease selected from schizophrenia, Parkinson's Disease, dementia, anxiety disorder, age associated memory impairment, depression, Alzheimer's Disease, attention deficit hyperactivity disorder (ADHD) or post-traumatic stress disorder (PTSD) in a mammal. 
Tvar iz patentnog zahtjeva 1, ili njena farmaceutski prihvatljiva sol dobivena adicijom kiseline, za uporabu u liječenju kognitivnog oštećenja povezanog s poremećajem ili bolesti odabranim između shizofrenije, Parkinsonove bolesti, demencije, tjeskobnog poremećaja, starosnog oštećenja pamćenja, depresije, Alzheimerove bolesti, hiperaktivnog poremećaja s nedostatkom pažnje (ADHD) ili posttraumatskog stresnog poremećaja (PTSD) u sisavaca.
The compound for use in treatment according to claim 4-8 in which the mammal is a human subject. 
Tvar za uporabu u liječenju u skladu s patentnim zahtjevom 4-8 gdje je sisavac čovjek.
The method of any one of claims 7 to 10, wherein the (±)-Δ9-tetrahydrocannabinol comprises at least 95% by weight, preferably at least 98% by weight and more preferably at least 99% by weight of trans-(-)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol based on the total amount of cannabinoids. 
Postupak prema bilo kojem od zahtjeva 1 do 14, naznačen time da (±)-Δ9-tertahidrokanabinol sadrži barem 95%, poželjno barem 98%, poželjnije barem 99% težinski trans-(-)-Δ9-tertahidrokanabinola i trans-(+)-Δ9-tertahidrokanabinola u odnosu na ukupnu količinu kanabinoida.
A conjugate comprising an antibody of claim 1 coupled to a therapeutic agent, wherein the therapeutic agent preferably is a toxin, a radioisotope, a drug or a cytotoxic agent. 
Konjugat koji sadrži antitijelo prema bilo kojem od patentnih zahtjeva 1 do 20 spojen za terapeutsko sredstvo, pri čemu je terapeutsko sredstvo poželjno toksin, radioaktivni izotop, lijek ili citotoksično sredstvo.
The antibody of any one of claims 2-15 wherein CLD18A2 has the amino acid sequence according to SEQ ID NO:2. 
Protutijelo iz patentnog zahtjeva 2 pri čemu CLD18A2 ima slijed aminokiselina prema SEQ ID NO: 2.
The antibody of any one of claims 2-9 wherein CLD18A1 has the amino acid sequence according to SEQ ID N0:8. 
Protutijelo iz bilo kojeg od patentnih zahtjeva 2-3 pri čemu CLD18A1 ima slijed aminokiselina prema SEQ ID NO: 8.
A conjugate comprising an antibody of any one of claims 1 to 20 coupled to a therapeutic agent, wherein the therapeutic agent preferably is a toxin, a radioisotope, a drug or a cytotoxic agent. 
Konjugat obuhvaća protutijelo iz bilo kojeg od patentnih zahtjeva 1 do 5 vezano za terapijski agens, pri čemu je terapijski agens poželjno toksin, radioizotop, lijek ili citotoksični agens.
The antibody of any one of claims 2-16 wherein CLD18A1 has the amino acid sequence according to SEQ ID NO:8. 
Protutijelo iz bilo kojeg od patentnih zahtjeva 2-3 pri čemu CLD18A1 ima slijed aminokiselina prema SEQ ID NO: 8.
A conjugate comprising an antibody of any one of claims 1 to 22 coupled to a therapeutic agent. The conjugate of claim 25 wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent. 
Konjugat obuhvaća protutijelo iz bilo kojeg od patentnih zahtjeva 1 do 5 vezano za terapijski agens, pri čemu je terapijski agens poželjno toksin, radioizotop, lijek ili citotoksični agens.
curving of the inner side of the said transparent stone (1), forming a space and leaving an outer shell (1.1), 
rezbarenje unutarnje strane navedenog transparentnog kamena (1), formirajući prostor i ostavljajući vanjsku ljusku (1.1),
connecting at least one three-dimensional object (5) to the inward facing surface of the said filling layer (2) at the very bottom, and closing the lower part of the stone (1). 
povezivanje barem jednog trodimenzionalnog objekta (5) na unutarnju površinu navedenog sloja punjenja (2) na samom dnu, i zatvaranje donjeg dijela kamena (1).
A method for creating a three-dimensional image inside a transparent stone (1) according to claim 1 wherein the said first designing process is at least a engraving (3) formed on the inward facing surface of the said outer shell (1.1) by curving. 
Postupak kreiranja trodimenzionalne slike unutar transparentnog kamena (1) prema zahtjevu 1, naznačen time da navedeni prvi postupak dizajniranja je najmanje gravura (3) formirana na unutarnjoj površini navedene vanjske ljuske (1.1) rezbarenjem.
A method for creating a three-dimensional image inside a transparent stone (1) according to any one of the above claims wherein the said first designing process is at least a relief (4) formed on the inward facing surface of the said outer shell (1.1) by embossing. 
Postupak kreiranja trodimenzionalne slike unutar transparentnog kamena (1) prema bilo kojem od predhodnih zahtjeva, naznačen time da navedeni prvi postupak dizajniranja je najmanje reljef (4) formiran na unutarnjoj površini navedene vanjske ljuske (1.1) utiskivanjem.